Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, targets glycolate oxidase to reduce hepatic oxalate production and urinary oxalate excretion, showing promise in addressing the underlying cause of progressive kidney failure in individuals with primary hyperoxaluria type 1 (PH1).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | 1.444 € | Backorder |
Description | Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, targets glycolate oxidase to reduce hepatic oxalate production and urinary oxalate excretion, showing promise in addressing the underlying cause of progressive kidney failure in individuals with primary hyperoxaluria type 1 (PH1). |
In vitro | Lumasiran sodium is utilized in the study of Primary Hyperoxaluria Type 1 (PH1). It functions by silencing the gene responsible for glycolate oxidase production, subsequently reducing glycolate oxidase levels. This inhibition blocks oxalate synthesis, the harmful metabolite linked to PH1's clinical symptoms[1]. |
In vivo | Lumasiran sodium is a liver-targeted therapeutic agent administered subcutaneously, functioning through RNA interference (RNAi) [2]. |
Cas No. | 1834612-06-4 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.